

[Emtricitabine](#)

Not recommended as an essential medicine

Section:

[6. Anti-infective medicines 6.4. Antiviral medicines 6.4.2. Antiretrovirals 6.4.2.1. Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors](#)

Codes ATC: [J05AF09](#)

EMLc

Indication

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Code ICD11: [1C62.Z](#)

INN

Emtricitabine

Type de médicament

Chemical agent

Type de liste

Liste de base

Additional notes

Emtricitabine (FTC) is an acceptable alternative to lamivudine (3TC), based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.

Formulations

Oral > Liquid: 10 mg per mL

Oral > Solid: 200 mg

Historique des statuts LME

Ajouté pour la première fois en 2007 ([TRS 946](#))

Modifié en 2007 ([TRS 950](#))

Retiré en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Limite d'âge

>3 months

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Emtricitabine](#)

DrugBank

[Emtricitabine](#)

Résumé des preuves et recommandation du comité d'experts



The Expert Committee recommended the removal of emtricitabine from the EML and EMLc on the basis that listing is not aligned with dosing guidelines in the 2013 WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (1), and also because of the availability of fixed-dose combination formulations containing emtricitabine. References: 1. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.